17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors
The incidence of ovarian cancer has been epidemiologically related to female reproductive events and hormone replacement therapy after menopause. This highlights the importance of evaluating the role of sexual steroid hormones in ovarian cancer by the expression of enzymes related to steroid hormone...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-11-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/12/12/EC-23-0315.xml |
| _version_ | 1827631769494487040 |
|---|---|
| author | Enrique Pedernera Flavia Morales-Vásquez María J Gómora Miguel A Almaraz Esteban Mena Delia Pérez-Montiel Elizabeth Rendon Horacio López-Basave Juan Maldonado-Cubas Carmen Méndez |
| author_facet | Enrique Pedernera Flavia Morales-Vásquez María J Gómora Miguel A Almaraz Esteban Mena Delia Pérez-Montiel Elizabeth Rendon Horacio López-Basave Juan Maldonado-Cubas Carmen Méndez |
| author_sort | Enrique Pedernera |
| collection | DOAJ |
| description | The incidence of ovarian cancer has been epidemiologically related to female reproductive events and hormone replacement therapy after menopause. This highlights the importance of evaluating the role of sexual steroid hormones in ovarian cancer by the expression of enzymes related to steroid hormone biosynthesis in the tumor cells. This study was aimed to evaluate the presence of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), aromatase and estrogen receptor alpha (ERα) in the tumor cells and their association with the overall survival in 111 patients diagnosed with primary ovarian tumors. Positive immunoreactivity for 17β-HSD1 was observed in 74% of the tumors. In the same samples, aromatase and ERα revealed 66% and 47% positivity, respectively. No association was observed of 17β-HSD1 expression with the histological subtypes and clinical stages of the tumor. The overall survival of patients was improved in 17β-HSD1-positive group in Kaplan–Meier analysis (P = 0.028), and 17β-HSD1 expression had a protective effect from multivariate proportional regression evaluation (HR = 0.44; 95% CI 0.24–0.9; P = 0.040). The improved survival was observed in serous epithelial tumors but not in nonserous ovarian tumors. The expression of 17β-HSD1 in the cells of the serous epithelial ovarian tumors was associated with an improved overall survival, whereas aromatase and ERα were not related to a better survival. The evaluation of hazard risk factors demonstrated that age and clinical stage showed worse prognosis, and 17β-HSD1 expression displayed a protective effect with a better survival outcome in patients of epithelial ovarian tumors. |
| first_indexed | 2024-03-09T14:26:44Z |
| format | Article |
| id | doaj.art-49644390e91e4a55a7840b45571824d0 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 |
| language | English |
| last_indexed | 2024-03-09T14:26:44Z |
| publishDate | 2023-11-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-49644390e91e4a55a7840b45571824d02023-11-28T06:49:45ZengBioscientificaEndocrine Connections2049-36142023-11-01121219https://doi.org/10.1530/EC-23-031517β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumorsEnrique Pedernera0Flavia Morales-Vásquez1María J Gómora2Miguel A Almaraz3Esteban Mena4Delia Pérez-Montiel5Elizabeth Rendon6Horacio López-Basave7Juan Maldonado-Cubas8Carmen Méndez9Universidad Nacional Autónoma de México, Facultad de Medicina, Departamento de Embriología y Genética, Ciudad de México, MéxicoInstituto Nacional de Cancerología, Ciudad de México, MéxicoUniversidad Nacional Autónoma de México, Facultad de Medicina, Departamento de Embriología y Genética, Ciudad de México, MéxicoUniversidad Nacional Autónoma de México, Facultad de Medicina, Departamento de Embriología y Genética, Ciudad de México, MéxicoUniversidad Nacional Autónoma de México, Facultad de Medicina, Secretaría General, Ciudad de México, México; Universidad La Salle, Posgrado de la Facultad de Ciencias Químicas, Ciudad de México, México Instituto Nacional de Cancerología, Ciudad de México, MéxicoHospital Militar de Especialidades de la Mujer y Neonatología. Ciudad de México, MéxicoInstituto Nacional de Cancerología, Ciudad de México, MéxicoUniversidad La Salle, Posgrado de la Facultad de Ciencias Químicas, Ciudad de México, MéxicoUniversidad Nacional Autónoma de México, Facultad de Medicina, Departamento de Embriología y Genética, Ciudad de México, MéxicoThe incidence of ovarian cancer has been epidemiologically related to female reproductive events and hormone replacement therapy after menopause. This highlights the importance of evaluating the role of sexual steroid hormones in ovarian cancer by the expression of enzymes related to steroid hormone biosynthesis in the tumor cells. This study was aimed to evaluate the presence of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), aromatase and estrogen receptor alpha (ERα) in the tumor cells and their association with the overall survival in 111 patients diagnosed with primary ovarian tumors. Positive immunoreactivity for 17β-HSD1 was observed in 74% of the tumors. In the same samples, aromatase and ERα revealed 66% and 47% positivity, respectively. No association was observed of 17β-HSD1 expression with the histological subtypes and clinical stages of the tumor. The overall survival of patients was improved in 17β-HSD1-positive group in Kaplan–Meier analysis (P = 0.028), and 17β-HSD1 expression had a protective effect from multivariate proportional regression evaluation (HR = 0.44; 95% CI 0.24–0.9; P = 0.040). The improved survival was observed in serous epithelial tumors but not in nonserous ovarian tumors. The expression of 17β-HSD1 in the cells of the serous epithelial ovarian tumors was associated with an improved overall survival, whereas aromatase and ERα were not related to a better survival. The evaluation of hazard risk factors demonstrated that age and clinical stage showed worse prognosis, and 17β-HSD1 expression displayed a protective effect with a better survival outcome in patients of epithelial ovarian tumors.https://ec.bioscientifica.com/view/journals/ec/12/12/EC-23-0315.xmlovarian cancerepithelial ovarian tumoroverall survival17β-hydroxysteroid dehydrogenasearomataseestrogen receptor |
| spellingShingle | Enrique Pedernera Flavia Morales-Vásquez María J Gómora Miguel A Almaraz Esteban Mena Delia Pérez-Montiel Elizabeth Rendon Horacio López-Basave Juan Maldonado-Cubas Carmen Méndez 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors Endocrine Connections ovarian cancer epithelial ovarian tumor overall survival 17β-hydroxysteroid dehydrogenase aromatase estrogen receptor |
| title | 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| title_full | 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| title_fullStr | 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| title_full_unstemmed | 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| title_short | 17β-hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| title_sort | 17β hydroxysteroid dehydrogenase type 1 improves survival in serous epithelial ovarian tumors |
| topic | ovarian cancer epithelial ovarian tumor overall survival 17β-hydroxysteroid dehydrogenase aromatase estrogen receptor |
| url | https://ec.bioscientifica.com/view/journals/ec/12/12/EC-23-0315.xml |
| work_keys_str_mv | AT enriquepedernera 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT flaviamoralesvasquez 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT mariajgomora 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT miguelaalmaraz 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT estebanmena 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT deliaperezmontiel 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT elizabethrendon 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT horaciolopezbasave 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT juanmaldonadocubas 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors AT carmenmendez 17bhydroxysteroiddehydrogenasetype1improvessurvivalinserousepithelialovariantumors |